# Silence Therapeutics plc: overview SLN · Nasdaq · CIK 1479615 · [Healthcare](/sectors/healthcare.md) Pages: [Overview](/companies/sln.md) · [Financials](/companies/sln/financials.md) · [Filings](/companies/sln/filings.md) · [Insiders](/companies/sln/insiders.md) Latest reported revenue: [$0](/filings/0001193125-26-341248.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 10, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-341248). ## Last eight quarters | Line item | Unit | period not labelled (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [1.5](/filings/0001193125-25-268116.md) | [25.3 d](/filings/0001193125-26-092591.md) | [0.1](/filings/0001193125-26-210446.md) | [0.2](/filings/0001193125-26-341248.md) | [0.2](/filings/0001193125-25-268116.md) | [0.0 d](/filings/0001193125-26-092591.md) | [0.4](/filings/0001193125-26-210446.md) | [0.0](/filings/0001193125-26-341248.md) | | Gross margin | % | [(142.9%)](/filings/0001193125-25-268116.md) | [91.9% d](/filings/0001193125-26-092591.md) | [62.0%](/filings/0001193125-26-210446.md) | [62.1%](/filings/0001193125-26-341248.md) | [59.7%](/filings/0001193125-25-268116.md) | [64.7% d](/filings/0001193125-26-092591.md) | [97.4%](/filings/0001193125-26-210446.md) | not reported | | Operating margin | % | [(2002.5%)](/filings/0001193125-25-268116.md) | [(17.2%) d](/filings/0001193125-26-092591.md) | [(20006.3%)](/filings/0001193125-26-210446.md) | [(10697.8%)](/filings/0001193125-26-341248.md) | [(16505.7%)](/filings/0001193125-25-268116.md) | [(36650.0%) d](/filings/0001193125-26-092591.md) | [(3729.1%)](/filings/0001193125-26-210446.md) | not reported | | Net margin | % | [(2372.8%)](/filings/0001193125-25-268116.md) | [48.6% d](/filings/0001193125-26-092591.md) | [(20091.5%)](/filings/0001193125-26-341248.md) | [(12211.6%)](/filings/0001193125-26-341248.md) | [(13181.1%)](/filings/0001193125-25-268116.md) | [(34617.6%) d](/filings/0001193125-26-092591.md) | [(3544.3%)](/filings/0001193125-26-341248.md) | not reported | | Diluted EPS | $ per share | [(0.25)](/filings/0001193125-25-268116.md) | not reported | [(0.20)](/filings/0001193125-26-210446.md) | [(0.19)](/filings/0001193125-26-341248.md) | [(0.15)](/filings/0001193125-25-268116.md) | not reported | [(0.11)](/filings/0001193125-26-210446.md) | [(0.09)](/filings/0001193125-26-341248.md) | | Free cash flow | $m | [(25.7) d](/filings/0001193125-25-268116.md) | [(27.5) d](/filings/0001193125-26-092591.md) | [(12.3)](/filings/0001193125-26-210446.md) | [(21.8) d](/filings/0001193125-26-341248.md) | [(10.9) d](/filings/0001193125-25-268116.md) | [(17.3) d](/filings/0001193125-26-092591.md) | [(15.6)](/filings/0001193125-26-210446.md) | [1.5 d](/filings/0001193125-26-341248.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [12.4](/filings/0000950170-24-030519.md) | [21.7](/filings/0000950170-25-029129.md) | [31.6](/filings/0001193125-26-092591.md) | [43.3](/filings/0001193125-26-092591.md) | [0.6](/filings/0001193125-26-092591.md) | | Gross margin | % | [39.9%](/filings/0000950170-24-030519.md) | [37.8%](/filings/0000950170-25-029129.md) | [59.3%](/filings/0000950170-25-029129.md) | [72.7%](/filings/0001193125-26-092591.md) | [61.5%](/filings/0001193125-26-092591.md) | | Operating margin | % | [(369.0%)](/filings/0000950170-24-030519.md) | [(281.9%)](/filings/0000950170-25-029129.md) | [(203.5%)](/filings/0000950170-25-029129.md) | [(146.4%)](/filings/0001193125-26-092591.md) | [(16292.8%)](/filings/0001193125-26-092591.md) | | Net margin | % | [(317.4%)](/filings/0000950170-24-030519.md) | [(232.4%)](/filings/0000950170-25-029129.md) | [(171.4%)](/filings/0000950170-25-029129.md) | [(104.7%)](/filings/0001193125-26-092591.md) | [(15851.9%)](/filings/0001193125-26-092591.md) | | Diluted EPS | $ per share | not reported | [(0.52)](/filings/0000950170-25-029129.md) | [(0.49)](/filings/0000950170-25-029129.md) | [(0.33)](/filings/0001193125-26-092591.md) | [(0.63)](/filings/0001193125-26-092591.md) | | Free cash flow | $m | [5.5](/filings/0000950170-24-030519.md) | [(57.2)](/filings/0000950170-25-029129.md) | [(49.5)](/filings/0000950170-25-029129.md) | [(67.9)](/filings/0001193125-26-092591.md) | [(62.3)](/filings/0001193125-26-092591.md) | - Revenue. XBRL Revenue: ifrs-full:RevenueFromContractsWithCustomers; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: ifrs-full:GrossProfit; Revenue: ifrs-full:RevenueFromContractsWithCustomers; Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities; Revenue: ifrs-full:RevenueFromContractsWithCustomers; Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLoss; Revenue: ifrs-full:RevenueFromContractsWithCustomers; Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities; Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/sln/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Siren, L.L.C.](/funds/2005245.md) | 2026-06-30 | $36.4m | 3,311,438 | | Added +400,000 | | [TCG Crossover Management, LLC](/funds/1839948.md) | 2026-06-30 | $33.3m | 3,033,560 | | Unchanged | | [Redmile Group, LLC](/funds/1425738.md) | 2026-06-30 | $23.8m | 2,164,777 | | Unchanged | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $14.8m | 1,346,731 | | Reduced −800,000 | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $14.8m | 1,346,731 | | Reduced −800,000 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $14.6m | 1,329,625 | | Added +94,818 | | [Nextech Invest Ltd.](/funds/1595430.md) | 2026-06-30 | $10.5m | 952,400 | | Unchanged | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $10.0m | 909,279 | | Reduced −164,912 | | [Tetragon Partners GP Ltd](/funds/1515070.md) | 2026-06-30 | $8.4m | 764,256 | | Added +134,095 | | [Soleus Capital Management, L.P.](/funds/1802630.md) | 2026-06-30 | $6.9m | 630,000 | | New +630,000 | ## Recent filings [All 268 filings](/companies/sln/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-19 | 12:05 ET | [8-K](/filings/0001193125-26-424695.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-424695 | | 2026-08-13 | 01:55 ET | [SCHEDULE 13D/A](/filings/0001104659-26-096202.md) | Ownership report, active investor, amended | 0001104659-26-096202 | | 2026-08-12 | 21:23 ET | [8-K](/filings/0001193125-26-347196.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-347196 | | 2026-08-10 | 11:57 ET | [8-K](/filings/0001193125-26-341293.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-341293 | | 2026-08-10 | 11:26 ET | [10-Q](/filings/0001193125-26-341248.md) | Quarterly report, period 2026-06-30 | 0001193125-26-341248 | | 2026-08-10 | 11:20 ET | [8-K](/filings/0001193125-26-341240.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-341240 | | 2026-07-16 | 21:20 ET | [8-K/A](/filings/0001193125-26-306251.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-306251 | | 2026-07-08 | 11:00 ET | [SCHEDULE 13D/A](/filings/0001104659-26-081559.md) | Ownership report, active investor, amended | 0001104659-26-081559 | | 2026-06-23 | 20:35 ET | [8-K](/filings/0001193125-26-279577.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-279577 | | 2026-06-16 | 21:00 ET | [8-K](/filings/0001193125-26-272814.md) | 5.07 Shareholder vote results | 0001193125-26-272814 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-092591.md), filed Mar 5, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/8f40f5ae-156a-4801-a427-4b822b3c8ea9) ## About the filer - CIK: 1479615 - Tickers: SLN, SLNCF - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: X0 - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.